美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

避孕概念

2,134.87

-53.2173-2.43%

涨家数：1

跌家数：4

平家数：- -

市盈率：- -

高：2,211.51

开：2,188.85

低：2,120.41

收：2,188.09

成交量：2,644.41万

成交额：2.30亿

市值：343.06亿

流通市值：336.06亿

数据加载中...

总览新闻资讯

Femasys Inc 修订案将于2025年12月31日生效：移除票据与认股权证中的股份合并事件调整条款

Veru Inc.启动恩博沙姆与司美格鲁肽联合疗法用于高质量减重的2B期平台临床试验，首位患者入组

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK4584/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"避孕概念","latestPrice":2134.8713,"timestamp":1774036799999,"preClose":2188.0886,"halted":0,"volume":26444077,"delay":0,"changeRate":-0.024321,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-53.217285,"latestTime":"03-20 16:00:00 EDT","open":2188.8494,"high":2211.5076,"low":2120.4114,"amount":229570705.612464,"amplitude":0.041633,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.447776,"peRate":25.857654,"turnoverRate":0.017403,"increases":1,"decrements":4,"flats":0,"marketCap":34306294194,"floatMarketCap":33606037958},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2211.5076,"amplitude":0.041633,"preClose":2188.0886,"low":2120.4114,"pbRate":"4.447776","latestPrice":2134.8713,"volume":26444077,"delay":0,"open":2188.8494,"prevYearClose":2379.9924,"prevWeekClose":2130.6833,"prevMonthClose":2521.1123,"prevQuarterClose":2379.9924,"fiveDayClose":2130.6833,"twentyDayClose":2591.9956,"sixtyDayClose":2384.971,"secType":"PLATE","market":"US","turnoverRate":0.017403,"peRate":25.857654,"marketCap":34306294194,"floatMarketCap":33606037958,"timestamp":1774036799999,"nameCN":"避孕概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":1,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1141975391","title":"Femasys Inc 修订案将于2025年12月31日生效：移除票据与认股权证中的股份合并事件调整条款","url":"https://stock-news.laohu8.com/highlight/detail?id=1141975391","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141975391?lang=zh_cn&edition=fundamental","pubTime":"2026-03-21 05:19","pubTimestamp":1774041553,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会提交的最新文件，Femasys Inc 已通过一项修订案，该修订案将自2025年12月31日起正式生效。此次修订的核心内容是，从公司发行的票据和认股权证的相关条款中，移除了针对股份合并事件的调整机制。这一变动意味着，自生效日起，若公司进行股份合并，将不再触发对上述票据和认股权证的行权价格或转换比率等条款的自动调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","FEMY","BK4082","BK4539"],"gpt_icon":0},{"id":"1168049288","title":"Veru Inc.启动恩博沙姆与司美格鲁肽联合疗法用于高质量减重的2B期平台临床试验，首位患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1168049288","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168049288?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:36","pubTimestamp":1773059779,"startTime":"0","endTime":"0","summary":"Veru Inc.宣布，其用于实现高质量减重的恩博沙姆（enobosarm）与司美格鲁肽（semaglutide）联合疗法的2B期平台临床试验已完成首位患者入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","VERU","BK4183","BK4584","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}